Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511151-18-01

Acronym

NL202100762

Enrollment

Registered

2024-11-25

Start date

2025-01-02

Completion date

Unknown

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

defined as international prognostic index > 2, Lymphoma, Patients with stage II-IV high risk diffuse large B-cell lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026